Reports Q2 revenue $44.1M, consensus $17.51M. The increase in revenue was primarily due to $30M of license revenue from the achievement of two Sanofi license extensions and a $5M clinical milestone achieved under Nurix’s collaboration with Gilead during the three months ended May 31. “During our second quarter, Nurix delivered important collaboration milestones, resulting in Sanofi’s extension of its license for our STAT6 program and FDA clearance of the IND for IRAK4 degrader GS-6791/NX-0479 in collaboration with Gilead,” said Arthur Sands, president and chief executive officer of Nurix. “We are now entering a transformative period as we advance bexobrutideg into pivotal studies in CLL and progress our efforts to bring degrader-based therapies to patients with autoimmune diseases and inflammation.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- NRIX Earnings this Week: How Will it Perform?
- Nurix announces EMA grant of Orphan Drug Designation for bexobrutideg
- Promising Clinical Data from Nurix Therapeutics’ BTK Degrader NX-5948 Supports Buy Rating
- Nurix Therapeutics management to meet with Oppenheimer
- Promising Developments in Nurix Therapeutics’ BTK Degrader Drive Buy Rating